A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | MicrobiomeTrials
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-12-09Est. Completion: 2027-07-16
Enrollment target: 189 participants
Locations
Local Institution - 0029, Guangzhou, GD, China
Local Institution - 0015, Guangzhou, GD, China
Local Institution - 0013, Foshan, Guangdong, China
Local Institution - 0017, Maoming Shi, Guangdong, China
Local Institution - 0030, Shenzhen Shi, Guangdong, China
Local Institution - 0023, Liuzhou, Guangxi, China
Local Institution - 0014, Nanning, GX, China
Local Institution - 0011, Haikou, Hainan, China
Local Institution - 0012, Kunming, Yunnan, China
Local Institution - 0002, Haikou, China
Local Institution - 0016, Nanning, China
Local Institution - 0018, Rio, G, Greece
Local Institution - 0006, Athens, Greece
Local Institution - 0009, Goudi, Greece
Local Institution - 0007, Larissa, Greece
Local Institution - 0025, Hong Kong, HK, Hong Kong
Local Institution - 0026, Genova, GE, Italy
Local Institution - 0020, Orbassano, TO, Italy
Local Institution - 0028, Naples, Italy
Other microbiome trials you might be interested in
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine CarcinomaMetastatic Pancreatic AdenocarcinomaStage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Lung Small Cell CarcinomaUnresectable Malignant Solid NeoplasmUnresectable Neuroendocrine CarcinomaUnresectable Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemothera…